Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 74

Related Articles by Review for PubMed (Select 22610723)

1.

Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.

Childress AC.

Adv Ther. 2012 May;29(5):385-400. doi: 10.1007/s12325-012-0020-1. Epub 2012 May 18. Review.

PMID:
22610723
2.

Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.

Faraone SV, McBurnett K, Sallee FR, Steeber J, López FA.

Clin Ther. 2013 Nov;35(11):1778-93. doi: 10.1016/j.clinthera.2013.09.005. Epub 2013 Oct 16. Review.

PMID:
24139092
3.

Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents.

Connor DF, Arnsten AF, Pearson GS, Greco GF.

Expert Opin Pharmacother. 2014 Aug;15(11):1601-10. doi: 10.1517/14656566.2014.930437. Epub 2014 Jul 3. Review.

PMID:
24992513
4.

Guanfacine extended-release for attention-deficit/hyperactivity disorder (ADHD).

Sallee FR, Eaton K.

Expert Opin Pharmacother. 2010 Oct;11(15):2549-56. doi: 10.1517/14656566.2010.517523. Review.

PMID:
20831361
5.

Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder.

Bukstein OG, Head J.

Expert Opin Pharmacother. 2012 Oct;13(15):2207-13. doi: 10.1517/14656566.2012.721778. Epub 2012 Sep 7. Review.

PMID:
22957772
6.

Guanfacine extended-release: in attention deficit hyperactivity disorder.

Muir VJ, Perry CM.

Drugs. 2010 Sep 10;70(13):1693-702. doi: 10.2165/11205940-000000000-00000. Review.

PMID:
20731476
7.

The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.

Sallee FR.

Postgrad Med. 2010 Sep;122(5):78-87. doi: 10.3810/pgm.2010.09.2204. Review.

PMID:
20861591
8.

A review of the rationale and clinical utilization of α2-adrenoceptor agonists for the treatment of attention-deficit/hyperactivity and related disorders.

Sallee F, Connor DF, Newcorn JH.

J Child Adolesc Psychopharmacol. 2013 Jun;23(5):308-19. doi: 10.1089/cap.2013.0028. Review.

PMID:
23782125
9.

Guanfacine extended release in the treatment of attention deficit hyperactivity disorder in children and adolescents.

Connor DF, Rubin J.

Drugs Today (Barc). 2010 May;46(5):299-314. doi: 10.1358/dot.2010.46.5.1450095. Review.

PMID:
20517532
11.

Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.

Huang YS, Tsai MH.

CNS Drugs. 2011 Jul;25(7):539-54. doi: 10.2165/11589380-000000000-00000. Review. Erratum in: CNS Drugs. 2011 Nov 1;25(11):932. Dosage error in article text.

PMID:
21699268
12.

[Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].

Purper-Ouakil D, Fourneret P, Wohl M, Rénéric JP.

Encephale. 2005 May-Jun;31(3):337-48. Review. French.

PMID:
16142049
13.

Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder.

Martinez-Raga J, Knecht C, de Alvaro R.

Neuropsychiatr Dis Treat. 2015 May 28;11:1359-70. doi: 10.2147/NDT.S65735. eCollection 2015. Review.

14.

Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.

Wigal SB, Chae S, Patel A, Steinberg-Epstein R.

Semin Pediatr Neurol. 2010 Dec;17(4):230-6. doi: 10.1016/j.spen.2010.10.005. Review.

PMID:
21183129
15.

Guanfacine and guanfacine extended release: treatment for ADHD and related disorders.

Posey DJ, McDougle CJ.

CNS Drug Rev. 2007 Winter;13(4):465-74. Review.

PMID:
18078429
16.

Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.

Martinez-Raga J, Knecht C, Szerman N, Martinez MI.

CNS Drugs. 2013 Jan;27(1):15-30. doi: 10.1007/s40263-012-0019-9. Review.

PMID:
23160939
17.

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Garnock-Jones KP, Keating GM.

Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Review.

PMID:
19445548
18.

Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder.

Brams M, Mao AR, Doyle RL.

Postgrad Med. 2008 Sep;120(3):69-88. doi: 10.3810/pgm.2008.09.1909. Review.

PMID:
18824827
19.

Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.

Steer C, Froelich J, Soutullo CA, Johnson M, Shaw M.

CNS Drugs. 2012 Aug 1;26(8):691-705. doi: 10.2165/11634340-000000000-00000. Review.

PMID:
22762726
20.

Revisiting clonidine: an innovative add-on option for attention-deficit/hyperactivity disorder.

Childress AC, Sallee FR.

Drugs Today (Barc). 2012 Mar;48(3):207-17. doi: 10.1358/dot.2012.48.3.1750904. Review.

PMID:
22462040
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk